Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × darolutamide × 30 days × Clear all

Phase

Phase 2 6 Phase 1 5 Phase 3 3 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Bulbo-Spinal Atrophy, X-Linked 1

Interventions

pembrolizumab 52 Carboplatin 37 Specimen Handling 35 Biopsy 33 Magnetic Resonance Spectroscopy 32 Cyclophosphamide 29 Nivolumab 25 Dexamethasone 22 fludarabine 21 venetoclax 19 Paclitaxel 19 Gemcitabine 19 Bevacizumab 19 Pemetrexed 17 Temozolomide 15 Rituximab 14 Cisplatin 14 Prednisone 13 Lenalidomide 13 Azacitidine 13 atezolizumab 12 Cetuximab 12 Vincristine 10 Fulvestrant 10 Radiotherapy 9 Irinotecan 9 fludarabine phosphate 8 durvalumab 8 carfilzomib 8 aldesleukin 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07190300 2026-03-02

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting

Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon ⚡